← Back to Search

Education Program for Increasing Clinical Trial Participation in Cancer

N/A

Recruiting

Led By Electra D Paskett, PhD

Research Sponsored by Ohio State University Comprehensive Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Adult males and females 18 years of age and older from Ohio

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 2 years

Awards & highlights

Study Summary

This trial is researching ways to increase knowledge and participation in clinical trials among minorities and rural populations.

Who is the study for?

This trial is for adults over 18 in Ohio, particularly from racial/ethnic minority and rural populations. It aims to increase their participation in clinical trials. Those who cannot give informed consent due to cognitive impairment are excluded.Check my eligibility

What is being tested?

The study tests an educational program designed by community health educators to boost understanding and involvement in clinical trials among underrepresented groups, focusing on the benefits of such research.See study design

What are the potential side effects?

Since this trial involves education and surveys rather than medical treatments, there are no direct physical side effects. However, participants may experience increased awareness about clinical trials.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am an adult over 18 years old living in Ohio.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in knowledge

Prior clinical trial participation status

Trial Design

1Treatment groups

Experimental Treatment

Group I: Health Services Research (educational session and materials)Experimental Treatment3 Interventions

Participants attend an educational session with CHEs and receive educational materials on study.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Health Education

2014

Completed Phase 3

~4010

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Ohio State University Comprehensive Cancer CenterLead Sponsor

320 Previous Clinical Trials

289,920 Total Patients Enrolled

Electra D Paskett, PhDPrincipal InvestigatorOhio State University Comprehensive Cancer Center

5 Previous Clinical Trials

1,652 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment still available for this clinical study?

"Affirmative. According to the information present on clinicaltrials.gov, this investigation is actively enrolling patients; it was first published on August 15th 2022 and has since seen a number of edits. The study requires 175 subjects from one site for completion."

Answered by AI

What is the participant size of this medical experiment?

"Indeed, the data hosted on clinicaltrials.gov confirms that this medical trial is presently recruiting patients across one location. This investigation was first initiated on August 15th 2022 with its most recent update occurring October 26th 2023 and has a goal of enlisting 175 participants."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Evaluation of an Education Program to Increase Knowledge and Participation in Clinical Trials Among Racial/Ethnic and Rural Populations

Electra Paskett 2022. "Evaluation of an Education Program to Increase Knowledge and Participation in Clinical Trials Among Racial/Ethnic and Rural Populations". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06112002.